Literature DB >> 31723799

The First Year of HemaSphere and Many More to Come.

Andreas Engert1, Jan Cools2.   

Abstract

Year:  2018        PMID： 31723799      PMCID： PMC6745960          DOI： 10.1097/HS9.0000000000000161

Source DB:  PubMed          Journal:  Hemasphere        ISSN： 2572-9241


× No keyword cloud information.
  10 in total

1.  National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment.

Authors:  Peter B Bach
Journal:  N Engl J Med       Date:  2018-08-15       Impact factor: 91.245

2.  FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.

Authors:  Peter B Bach; Sergio A Giralt; Leonard B Saltz
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

Review 3.  Immunological Mechanisms Underneath the Efficacy of Cancer Therapy.

Authors:  Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer
Journal:  Cancer Immunol Res       Date:  2016-11       Impact factor: 11.151

4.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

5.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

6.  Controversies in the Treatment of Classical Hodgkin Lymphoma.

Authors:  Dennis A Eichenauer; Marc André; Peter Johnson; Alexander Fossa; Olivier Casasnovas; Andreas Engert
Journal:  Hemasphere       Date:  2018-10-02

7.  Immunotherapy Frontiers in Hematology.

Authors:  Simon Hallam
Journal:  Hemasphere       Date:  2017-12-20

Review 8.  Immune Checkpoint Inhibition in Hodgkin Lymphoma.

Authors:  Ryan H Moy; Anas Younes
Journal:  Hemasphere       Date:  2018-02-16

Review 9.  Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe.

Authors:  Jochen Buechner; Marie José Kersten; Miriam Fuchs; Florence Salmon; Ulrich Jäger
Journal:  Hemasphere       Date:  2018-02-02

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.